Compare GSK plc (GSK) vs Americas Gold and Silver Corporation Common Shares no par value (USAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Americas Gold and Silver Corporation Common Shares no par value — how do they compare? GSK plc trades at $48.84 (market cap $96.45B), while Americas Gold and Silver Corporation Common Shares no par value trades at $3.8 (market cap $1.26B). The key difference: GSK plc is far larger — about 76.5× Americas Gold and Silver Corporation Common Shares no par value's market cap, and GSK plc pays a 3.79% dividend while Americas Gold and Silver Corporation Common Shares no par value pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Americas Gold and Silver Corporation Common Shares no par value for 0 Days on average.
| GSK | USAS | |
|---|---|---|
Market Cap | $96.45B | $1.26B |
Volume | 7,087,457 | 3,948,671 |
Sector | Health | Basic Materials |
52-Week High | $61.18 | $10.03 |
52-Week Low | $43.24 | $3.59 |
Typical Hold Time | 93 Days | 0 Days |
Enterprise Value | $116.51B | $1.19B |
Dividend Yield | 3.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.27, down 1.39% today, with a bearish technical signal from moving averages. The company shows strong profitability with 72.73% gross margins and 14.52% net income margin, supported by three consecutive quarterly earnings beats. Recent developments include a $750M cancer therapy acquisition and strategic focus on oncology growth targeting £40B in sales. Cash flow trends show consistent operational strength with $7.7B from operations in 2025.
GSK presents a mixed outlook with strong fundamentals offset by technical weakness. The stock offers value with a 14.84 P/E ratio and dividend yield, but faces headwinds from HIV patent expirations and bearish technical indicators. Analyst consensus leans cautious with 55% hold ratings, suggesting patience may be warranted despite the company's solid operational performance.
USAS trades at $4.02, down 4.29% on the day, reflecting ongoing volatility amid mixed operational performance. The company reported a net loss of $87.45M in 2025, though revenue is projected to grow to $182M in 2026 with a narrowing loss. Recent news highlights progress at its Galena and Cosalá mines, including high-grade silver discoveries and sustainability initiatives, signaling potential for future production growth.
The outlook is speculative, with high-risk turnaround potential driven by operational improvements and exposure to silver and critical minerals. Key risks include persistent negative profitability, high valuation multiples like EV/EBITDA of 455.68, and reliance on successful mine development. Analyst consensus is unanimously bullish, but investors must weigh execution risks against long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Americas Gold and Silver Corporation Common Shares no par value
Americas Gold and Silver Corporation is a Canada-based mining company that explores for and produces silver, along with by-product gold, copper, lead, and zinc. Its operating assets include the Galena Complex in Idaho and the Cosalá Operations in Sinaloa, Mexico.
Read more on USAS →
